Spine Biologics Market

Spine Biologics Market (Product: Bone Allografts, Bone Graft Substitute, Platelet Rich Plasma, Bone Marrow Aspirate Therapy, Demineralized Bone Matrix (DBM), and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Global Spine Biologics Market Outlook 2031

  • The global industry was valued at US$ 2.4 Bn in 2022
  • It is projected to grow at a CAGR of 4.1% from 2023 to 2031 and reach US$ 3.5 Bn by 2031

Analysts’ Viewpoint

Rise in prevalence of spinal disorders and increase in geriatric population is driving the global spine biologics market. Surge in elderly population is expected to propel demand for innovative and effective treatments for spinal conditions such as degenerative disc disease and spinal stenosis. Rise in adoption of spine biologics, which offer regenerative and minimally invasive solutions for spinal disorders, are likely to bolster market expansion. Furthermore, integration of spine biologics with advanced surgical techniques, such as minimally invasive procedures and robotic-assisted surgeries, which offer patients enhanced outcomes and faster recovery times, are projected to drive the global spine biologics market size.

Surge in investment in research & development to improve the safety and efficacy of spine biologics treatments offers lucrative opportunities to market players. Spine biologics companies are focusing on strategic launches and collaborations to enhance product offerings and expand their global footprint.

Spine Biologics Market

Global Spine Biologics Market Introduction

Spine biologics include biomaterials that are used to treat spinal cord injuries, degenerative disc disorders, and bone fusion procedures. Inflammation, healing, and remodeling are the primary processes that it uses to drive growth of bone formation.

Development of biologics that support the repair and regeneration of cartilaginous and bony structures is now underway, while certain biologics are intended to be utilized as a person's natural bone graft replacement.

Some of the spine biologics market trends are technological advances in bone grafting treatments. For instance, in April 2022, Royal Biologics launched Advanced-Cell, an advanced fusion bone grafting system for use in orthopedics. Advanced-Cell provides users with the ability to provide an optimal live cellular grafting option, combined with next-generation bone grafting technology to deliver point-of-care in a low cost bundle option.

Increase in geriatric population and rise in frequency of spine abnormalities are propelling the market. Surge in preference for minimally invasive procedures, rise in incidence of degenerative spine disorders, and surge in treatment cost are driving market expansion. Benefits of biologics such as faster recovery, minimal postoperative time, and ability to activate cellular growth is another major factor fueling global spine biologics market demand.

However, unfavorable reimbursement scenario, higher bone graft costs, and ethical concerns are likely to restrain market growth to some extent.

Development and commercialization of advanced stem cell therapies is also bolstering the market. Stem cells have shown promising potential in promoting tissue regeneration and improving patient outcomes in spinal fusion surgeries.

Various companies have developed innovative bone graft substitutes using biologic materials. For instance, in 2021, Medtronic offered INFUSE Bone Graft, which utilizes a recombinant human bone morphogenetic protein (rhBMP-2) to stimulate bone growth in spinal fusion surgeries. This product eliminates the need for harvesting bone from the patient's body and has shown positive clinical outcomes.

Adoption of these bone graft substitutes is increasing, as these offer advantages such as ease of use, reduced risk of infection, and improved patient outcomes. Research and development efforts are focused on enhancing the efficacy and safety of spine biologics, which is expected to provide opportunities for companies to develop novel products and therapies during the forecast period.

COVID-19 Impact on Spine Biologics Market

The COVID-19 pandemic has had a significant impact on the market. The pandemic resulted in a temporary decline in the market due to the postponement or cancellation of non-emergency elective surgeries. A number of healthcare systems redirected resources to prioritize the treatment of COVID-19 patients, leading to reduced demand for spine biologics.

Supply chain disruptions caused challenges in the production and distribution of spine biologics. Manufacturing delays, transportation constraints, and import/export restrictions led to potential shortages and limited availability of these products.

Stem cell treatments, which have shown promise in spinal fusion surgeries, experienced reduced demand as healthcare facilities focused on COVID-19 management. Limited availability of stem cell-based products and restrictions on research activities further hampered their utilization.

However, as vaccination efforts expanded and healthcare systems adapted to the pandemic, the spine biologics market started to recover. Resumption of elective surgeries and growing demand for advanced spinal treatments provided opportunities for market growth. Ongoing research and development efforts in the field of spine biologics are expected to fuel market expansion in the post-pandemic period.

Structural Support and Aid in Fusion Augmenting Bone Allografts Segment

In terms of product, the bone allografts segment held largest global spine biologics market share in 2022. The trend is expected to continue during the forecast period. This is ascribed to factors such as rise in prevalence of spinal disorders and advancements in processing techniques.

Spinal allografts provide structural support and aid in fusion, making them a crucial component in spinal fusion surgeries. Companies such as Medtronic, NuVasive, and Globus Medical have been key players in the spinal biologics market, offering a range of allograft products to address the needs of patients with spinal disorders.

Reduced Tissue Damage and Faster Recovery Driving Minimally Invasive Surgery Segment

Based on surgery type, the minimally invasive surgery segment dominated the global market in 2022. This is ascribed to advantages such as reduced tissue damage, shorter hospital stay, and faster recovery. As more patients and surgeons prefer minimally invasive approaches, the demand for spine biologics that complement these procedures is expected to increase.

Availability of Specialized Spine Centers and Multidisciplinary Teams in Hospitals

In terms of end-user, the hospitals segment accounted for leading share of the global spine biologics market in 2022. Hospitals serve as major healthcare providers and have the infrastructure and resources to perform complex spinal procedures that often require the use of biologics.

Hospitals typically have specialized spine centers and multidisciplinary teams of healthcare professionals dedicated to spinal treatments. Their expertise, coupled with the availability of advanced imaging and surgical facilities, positions hospitals as key players in the spine biologics market.

Regional Analysis of Global Spine Biologics Industry

According to the global market report, North America accounted for significant share of the global market in 2022. This is ascribed to large geriatric population, increase in adoption of minimally invasive procedure, and rise in prevalence of spine disorders such as spondylolisthesis, spinal stenosis, and disc-related issue.

According to the American Association of Neurological Surgeons, an estimated 17,000 new cases of spinal cord injury are reported in the U.S. every year. Thus, a large spinal cord injury population is likely to drive demand for treatment of disorders, wherein spinal biologics plays an important role in diagnosis.

As per the market forecast, Asia Pacific is expected to witness significant spine biologics market expansion during the forecast period. This is ascribed to increase in geriatric population, rise in prevalence of spinal disorders, growing healthcare infrastructure, and improving access to advanced spinal treatments in countries such as China, India, and Japan.

Analysis of Key Players

The report concludes with the company profiles section that includes key information about the major players. Companies focus on strategies such as new product launches, mergers, and partnerships & collaborations to compete in the marketplace.

Major spine biologics companies are Johnson & Johnson (Depuy Synthes), Orthofix Medical, Inc., Stryker Corporation, Zimmer Biomet, Arthrex, Inc., Exactech, Inc., Spine Wave, Inc., Medtronic plc, and NuVasive, Inc.

Key Developments in Global Spine Biologics Market

  • In April 2023, PUR Biologics, a subsidiary of HippoFi, Inc., launched PURcore, a unique moldable synthetic with an interconnected micro-pore structure for spine surgery. PURcore allows for the rapid colonization of the patient's own cells and growth factors which promotes bone regeneration and healing.
  • In February 2022, Orthofix Medical, Inc. expanded the full market launch of Opus BA, a synthetic bioactive bone graft solution for cervical and lumbar spine fusion procedures. Furthermore, Opus BA can be used to fill bone voids or gaps in the skeletal system that are not intrinsic to the stability of bony structure.
  • In April 2023, Bone Biologics Corporation received approval from Human Research Ethics Committee (HREC) for the first of a planned multicenter pilot clinical trial to evaluate the Company’s NB1 bone graft in Australia. This pilot study will evaluate the safety and effectiveness of NB1 in 30 adult subjects who undergo transforaminal lumbar interbody fusion (TLIF) to treat degenerative disc disease (DDD).

Prominent players have been profiled in the spine biologics market report based on parameters such as company overview, financial overview, strategies, portfolio, segments, and recent developments.

Global Spine Biologics Market Snapshot

Attribute Detail

Size in 2022

US$ 2.4 Bn

Forecast (Value) in 2031

US$ 3.5 Bn

Growth Rate (CAGR)

4.1%

Forecast Period

2023-2031

Historical Data Available for

2017-2021

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Segmentation

  • Product
    • Bone Allografts
    • Bone Graft Substitute
    • Platelet Rich Plasma
    • Bone Marrow Aspirate Therapy
    • Demineralized Bone Matrix (DBM)
    • Others
  • Surgery Type
    • Minimally Invasive Surgery
    • Open Surgery
  • Application
    • Spinal Fusion
    • Spinal Non-union and Fracture Repair
    • Degenerative Disc Disease Treatment
    • Other Applications
  • End-user
    • Hospitals
    • Spinal Surgery Centers
    • Others

Regions Covered

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • Japan
  • India
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Johnson & Johnson (Depuy Synthes)
  • Orthofix Medical, Inc.
  • Stryker Corporation
  • Zimmer Biomet
  • Arthrex, Inc.
  • Exactech, Inc.
  • Spine Wave, Inc.
  • Medtronic plc
  • NuVasive, Inc.

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global spine biologics market in 2022?

The global industry was valued at US$ 2.4 Bn in 2022.

How big will the spine biologics industry be by 2031?

It is projected to reach more than US$ 3.5 Bn by 2031.

What will be the CAGR of the global spine biologics business during the forecast period?

The market is anticipated to grow at a CAGR of 4.1% from 2023 to 2031.

Which are the prominent spine biologics drivers?

Rise in prevalence of spinal disorders, increase in geriatric population, and technological advances in bone grafting treatments are driving the market.

Which surgery type segment held leading market share of the spine biologics?

The minimally invasive surgery segment accounted for significant share in 2022.

Which region will account for major market share of the spine biologics during the forecast period?

North America is expected to account for the largest share of the market from 2023 to 2031.

Who are the prominent spine biologics players?

Johnson and Johnson (Depuy Synthes), Orthofix Medical, Inc., Stryker Corporation, Zimmer Biomet, Arthrex, Inc., Exactech, Inc., Spine Wave, Inc., Medtronic plc, and NuVasive, Inc. are the prominent players in the market.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Spine Biologics Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Segment Definition

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Spine Biologics Market Analysis and Forecast, 2017-2031

            4.4.1. Market Revenue Projections (US$ Mn)

        4.5. Porter’s Five Forces Analysis

    5. Key Insights

        5.1. Technological Advancements

        5.2. Reimbursement Scenario by Region/Globally

        5.3. Regulatory Scenario by Region/Globally

        5.4. Pipeline Analysis

        5.5. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)

    6. Global Spine Biologics Market Analysis and Forecast, by Product

        6.1. Introduction & Definition

        6.2. Key Findings/Developments

        6.3. Market Value Forecast, by Product, 2017-2031

            6.3.1. Bone Allografts

            6.3.2. Bone Graft Substitute

            6.3.3. Platelet Rich Plasma

            6.3.4. Bone Marrow Aspirate Therapy

            6.3.5. Demineralized Bone Matrix (DBM)

            6.3.6. Others

        6.4. Market Attractiveness Analysis, by Product

    7. Global Spine Biologics Market Analysis and Forecast, by Surgery Type

        7.1. Introduction & Definition

        7.2. Key Findings/Developments

        7.3. Market Value Forecast, by Surgery Type, 2017-2031

            7.3.1. Minimally Invasive Surgery

            7.3.2. Open Surgery

        7.4. Market Attractiveness Analysis, by Surgery Type

    8. Global Spine Biologics Market Analysis and Forecast, by Application

        8.1. Introduction & Definition

        8.2. Key Findings/Developments

        8.3. Market Value Forecast, by Application, 2017-2031

            8.3.1. Spinal Fusion

            8.3.2. Spinal Non-union & Fracture Repair

            8.3.3. Degenerative Disc Disease Treatment

            8.3.4. Other Applications

        8.4. Market Attractiveness Analysis, by Application

    9. Global Spine Biologics Market Analysis and Forecast, by End-user

        9.1. Introduction & Definition

        9.2. Key Findings/Developments

        9.3. Market Value Forecast, by End-user, 2017-2031

            9.3.1. Hospitals

            9.3.2. Spinal Surgery Centers

            9.3.3. Others

        9.4. Market Attractiveness Analysis, by End-user

    10. Global Spine Biologics Market Analysis and Forecast, by Region

        10.1. Key Findings

        10.2. Market Value Forecast, by Region, 2017-2031

            10.2.1. North America

            10.2.2. Europe

            10.2.3. Asia Pacific

            10.2.4. Latin America

            10.2.5. Middle East & Africa

        10.3. Market Attractiveness Analysis, by Region

    11. North America Spine Biologics Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Product, 2017-2031

            11.2.1. Bone Allografts

            11.2.2. Bone Graft Substitute

            11.2.3. Platelet Rich Plasma

            11.2.4. Bone Marrow Aspirate Therapy

            11.2.5. Demineralized Bone Matrix (DBM)

            11.2.6. Others

        11.3. Market Value Forecast, by Surgery Type, 2017-2031

            11.3.1. Minimally Invasive Surgery

            11.3.2. Open Surgery

        11.4. Market Value Forecast, by Application, 2017-2031

            11.4.1. Spinal Fusion

            11.4.2. Spinal Non-union & Fracture Repair

            11.4.3. Degenerative Disc Disease Treatment

            11.4.4. Other Applications

        11.5. Market Value Forecast, by End-user, 2017-2031

            11.5.1. Hospitals

            11.5.2. Spinal Surgery Centers

            11.5.3. Others

        11.6. Market Value Forecast, by Country, 2017-2031

            11.6.1. U.S.

            11.6.2. Canada

        11.7. Market Attractiveness Analysis

            11.7.1. By Product

            11.7.2. By Surgery Type

            11.7.3. By Application

            11.7.4. By End-user

            11.7.5. By Country

    12. Europe Spine Biologics Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Product, 2017-2031

            12.2.1. Bone Allografts

            12.2.2. Bone Graft Substitute

            12.2.3. Platelet Rich Plasma

            12.2.4. Bone Marrow Aspirate Therapy

            12.2.5. Demineralized Bone Matrix (DBM)

            12.2.6. Others

        12.3. Market Value Forecast, by Surgery Type, 2017-2031

            12.3.1. Minimally Invasive Surgery

            12.3.2. Open Surgery

        12.4. Market Value Forecast, by Application, 2017-2031

            12.4.1. Spinal Fusion

            12.4.2. Spinal Non-union & Fracture Repair

            12.4.3. Degenerative Disc Disease Treatment

            12.4.4. Other Applications

        12.5. Market Value Forecast, by End-user, 2017-2031

            12.5.1. Hospitals

            12.5.2. Spinal Surgery Centers

            12.5.3. Others

        12.6. Market Value Forecast, by Country/Sub-region, 2017-2031

            12.6.1. Germany

            12.6.2. U.K.

            12.6.3. France

            12.6.4. Italy

            12.6.5. Spain

            12.6.6. Rest of Europe

        12.7. Market Attractiveness Analysis

            12.7.1. By Product

            12.7.2. By Surgery Type

            12.7.3. By Application

            12.7.4. By End-user

            12.7.5. By Country/Sub-region

    13. Asia Pacific Spine Biologics Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Product, 2017-2031

            13.2.1. Bone Allografts

            13.2.2. Bone Graft Substitute

            13.2.3. Platelet Rich Plasma

            13.2.4. Bone Marrow Aspirate Therapy

            13.2.5. Demineralized Bone Matrix (DBM)

            13.2.6. Others

        13.3. Market Value Forecast, by Surgery Type, 2017-2031

            13.3.1. Minimally Invasive Surgery

            13.3.2. Open Surgery

        13.4. Market Value Forecast, by Application, 2017-2031

            13.4.1. Spinal Fusion

            13.4.2. Spinal Non-union & Fracture Repair

            13.4.3. Degenerative Disc Disease Treatment

            13.4.4. Other Applications

        13.5. Market Value Forecast, by End-user, 2017-2031

            13.5.1. Hospitals

            13.5.2. Spinal Surgery Centers

            13.5.3. Others

        13.6. Market Value Forecast, by Country/Sub-region, 2017-2031

            13.6.1. China

            13.6.2. Japan

            13.6.3. India

            13.6.4. Australia & New Zealand

            13.6.5. Rest of Asia Pacific

        13.7. Market Attractiveness Analysis

            13.7.1. By Product

            13.7.2. By Surgery Type

            13.7.3. By Application

            13.7.4. By End-user

            13.7.5. By Country/Sub-region

    14. Latin America Spine Biologics Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast, by Product, 2017-2031

            14.2.1. Bone Allografts

            14.2.2. Bone Graft Substitute

            14.2.3. Platelet Rich Plasma

            14.2.4. Bone Marrow Aspirate Therapy

            14.2.5. Demineralized Bone Matrix (DBM)

            14.2.6. Others

        14.3. Market Value Forecast, by Surgery Type, 2017-2031

            14.3.1. Minimally Invasive Surgery

            14.3.2. Open Surgery

        14.4. Market Value Forecast, by Application, 2017-2031

            14.4.1. Spinal Fusion

            14.4.2. Spinal Non-union & Fracture Repair

            14.4.3. Degenerative Disc Disease Treatment

            14.4.4. Other Applications

        14.5. Market Value Forecast, by End-user, 2017-2031

            14.5.1. Hospitals

            14.5.2. Spinal Surgery Centers

            14.5.3. Others

        14.6. Market Value Forecast, by Country/Sub-region, 2017-2031

            14.6.1. Brazil

            14.6.2. Mexico

            14.6.3. Rest of Latin America

        14.7. Market Attractiveness Analysis

            14.7.1. By Product

            14.7.2. By Surgery Type

            14.7.3. By Application

            14.7.4. By End-user

            14.7.5. By Country/Sub-region

    15. Middle East & Africa Spine Biologics Market Analysis and Forecast

        15.1. Introduction

            15.1.1. Key Findings

        15.2. Market Value Forecast, by Product, 2017-2031

            15.2.1. Bone Allografts

            15.2.2. Bone Graft Substitute

            15.2.3. Platelet Rich Plasma

            15.2.4. Bone Marrow Aspirate Therapy

            15.2.5. Demineralized Bone Matrix (DBM)

            15.2.6. Others

        15.3. Market Value Forecast, by Surgery Type, 2017-2031

            15.3.1. Minimally Invasive Surgery

            15.3.2. Open Surgery

        15.4. Market Value Forecast, by Application, 2017-2031

            15.4.1. Spinal Fusion

            15.4.2. Spinal Non-union & Fracture Repair

            15.4.3. Degenerative Disc Disease Treatment

            15.4.4. Other Applications

        15.5. Market Value Forecast, by End-user, 2017-2031

            15.5.1. Hospitals

            15.5.2. Spinal Surgery Centers

            15.5.3. Others

        15.6. Market Value Forecast, by Country/Sub-region, 2017-2031

            15.6.1. GCC Countries

            15.6.2. South Africa

            15.6.3. Rest of Middle East & Africa

        15.7. Market Attractiveness Analysis

            15.7.1. By Product

            15.7.2. By Surgery Type

            15.7.3. By Application

            15.7.4. By End-user

            15.7.5. By Country/Sub-region

    16. Competition Landscape

        16.1. Market Player - Competition Matrix (by tier and size of companies)

        16.2. Market Share Analysis, by Company, 2022

        16.3. Company Profiles

            16.3.1. Johnson And Johnson (Depuy Synthes)

                16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.1.2. Product Portfolio

                16.3.1.3. Financial Overview

                16.3.1.4. SWOT Analysis

                16.3.1.5. Strategic Overview

            16.3.2. Orthofix Medical Inc.

                16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.2.2. Product Portfolio

                16.3.2.3. Financial Overview

                16.3.2.4. SWOT Analysis

                16.3.2.5. Strategic Overview

            16.3.3. Stryker Corporation

                16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.3.2. Product Portfolio

                16.3.3.3. Financial Overview

                16.3.3.4. SWOT Analysis

                16.3.3.5. Strategic Overview

            16.3.4. Zimmer Biomet

                16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.4.2. Product Portfolio

                16.3.4.3. Financial Overview

                16.3.4.4. SWOT Analysis

                16.3.4.5. Strategic Overview

            16.3.5. Arthrex, Inc.

                16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.5.2. Product Portfolio

                16.3.5.3. Financial Overview

                16.3.5.4. SWOT Analysis

                16.3.5.5. Strategic Overview

            16.3.6. Exactech, Inc.

                16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.6.2. Product Portfolio

                16.3.6.3. Financial Overview

                16.3.6.4. SWOT Analysis

                16.3.6.5. Strategic Overview

            16.3.7. Spine Wave, Inc.

                16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.7.2. Product Portfolio

                16.3.7.3. Financial Overview

                16.3.7.4. SWOT Analysis

                16.3.7.5. Strategic Overview

            16.3.8. Medtronic plc

                16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.8.2. Product Portfolio

                16.3.8.3. Financial Overview

                16.3.8.4. SWOT Analysis

                16.3.8.5. Strategic Overview

            16.3.9. NuVasive, Inc.

                16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.9.2. Product Portfolio

                16.3.9.3. Financial Overview

                16.3.9.4. SWOT Analysis

                16.3.9.5. Strategic Overview

    List of Tables

    Table 01: Global Spine Biologics Market Value (US$ Mn) Forecast, by Product, 2022 and 2031

    Table 02: Global Spine Biologics Market Value (US$ Mn) Forecast, by Surgery Type, 2017-2031

    Table 03: Global Spine Biologics Market Value (US$ Mn) Forecast, by Application, 2017-2031

    Table 04: Global Spine Biologics Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    Table 05: Global Spine Biologics Market Value (US$ Mn) Forecast, by Region, 2017-2031

    Table 06: North America Spine Biologics Market Value (US$ Mn) Forecast, by Product, 2017-2031

    Table 07: North America Spine Biologics Market Value (US$ Mn) Forecast, by Surgery Type, 2017-2031

    Table 08: North America Spine Biologics Market Value (US$ Mn) Forecast, by Application, 2017-2031

    Table 09: North America Spine Biologics Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    Table 10: North America Biologics Market Value Share Analysis, by Country, 2022 and 2031

    Table 11: Europe Spine Biologics Market Value (US$ Mn) Forecast, by Product, 2017-2031

    Table 12: Europe Spine Biologics Market Value (US$ Mn) Forecast, by Surgery Type, 2017-2031

    Table 13: Europe Spine Biologics Market Value (US$ Mn) Forecast, by Application, 2017-2031

    Table 14: Europe Spine Biologics Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    Table 15: Asia Pacific Spine Biologics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 16: Asia Pacific Spine Biologics Market Value (US$ Mn) Forecast, by Product, 2017-2031

    Table 17: Asia Pacific Spine Biologics Market Value (US$ Mn) Forecast, by Surgery Type, 2017-2031

    Table 18: Asia Pacific Spine Biologics Market Value (US$ Mn) Forecast, by Application, 2017-2031

    Table 19: Asia Pacific Spine Biologics Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    Table 20: Latin America Spine Biologics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 21: Latin America Spine Biologics Market Value (US$ Mn) Forecast, by Product, 2017-2031

    Table 22: Latin America Spine Biologics Market Value (US$ Mn) Forecast, by Surgery Type, 2017-2031

    Table 23: Latin America Spine Biologics Market Value (US$ Mn) Forecast, by Application, 2017-2031

    Table 24: Latin America Spine Biologics Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    Table 25: Middle East & Africa Spine Biologics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 26: Middle East & Africa Spine Biologics Market Value (US$ Mn) Forecast, by Product, 2017-2031

    Table 27: Middle East & Africa Spine Biologics Market Value (US$ Mn) Forecast, by Surgery Type, 2017-2031

    Table 28: Middle East & Africa Spine Biologics Market Value (US$ Mn) Forecast, by Application, 2017-2031

    Table 29: Middle East & Africa Spine Biologics Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    List of Figures

    Figure 01: Global Spine Biologics Market Value Share Analysis, by Product, 2022 and 2031

    Figure 02: Global Spine Biologics Market Attractiveness Analysis, Product, 2023-2031

    Figure 03: Global Spine Biologics Market Revenue (US$ Mn), by Bone Allografts, 2017-2031

    Figure 04: Global Spine Biologics Market Revenue (US$ Mn), by Bone Graft Substitute, 2017-2031

    Figure 05: Global Spine Biologics Market Revenue (US$ Mn), by Platelet Rich Plasma, 2017-2031

    Figure 06: Global Spine Biologics Market Revenue (US$ Mn), by Bone Marrow Aspirate Therapy, 2017-2031

    Figure 07: Global Spine Biologics Market Revenue (US$ Mn), by Demineralized Bone Matrix (DBM), 2017-2031

    Figure 08: Global Spine Biologics Market Revenue (US$ Mn), by Others, 2017-2031

    Figure 09: Global Spine Biologics Market Value Share Analysis, by Surgery Type, 2022 and 2031

    Figure 10: Global Spine Biologics Market Attractiveness Analysis, by Surgery Type, 2023-2031

    Figure 11: Global Spine Biologics Market Revenue (US$ Mn), by Minimally Invasive Surgery, 2017-2031

    Figure 12: Global Spine Biologics Market Revenue (US$ Mn), by Open Surgery, 2017-2031

    Figure 13: Global Spine Biologics Market Value Share Analysis, by Application, 2022 and 2031

    Figure 14: Global Spine Biologics Market Attractiveness Analysis, Application, 2023-2031

    Figure 15: Global Spine Biologics Market Revenue (US$ Mn), by Spinal Fusion, 2017-2031

    Figure 16: Global Spine Biologics Market Revenue (US$ Mn), by Spinal Non-union & Fracture Repair, 2017-2031

    Figure 17: Global Spine Biologics Market Revenue (US$ Mn), by Degenerative Disc Disease Treatment, 2017-2031

    Figure 18: Global Spine Biologics Market Revenue (US$ Mn), by Other Applications, 2017-2031

    Table 19: Europe Spine Biologics Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    Figure 20: Global Spine Biologics Market Attractiveness Analysis, End-user, 2023-2031

    Figure 21: Global Spine Biologics Market Revenue (US$ Mn), by Hospitals, 2017-2031

    Figure 22: Global Spine Biologics Market Revenue (US$ Mn), by Spinal Surgery Centers, 2017-2031

    Figure 23: Global Spine Biologics Market Revenue (US$ Mn), by Others

    Figure 24: Global Spine Biologics Market Value Share Analysis, by Region, 2022 and 2031

    Figure 25: Global Spine Biologics Market Attractiveness Analysis, by Region, 2023-2031

    Figure 26: North America Spine Biologics Market Value (US$ Mn) Forecast, 2017-2031

    Figure 27: North America Spine Biologics Market Value Share Analysis, by Country, 2022 and 2031

    Figure 28: North America Spine Biologics Market Attractiveness Analysis, by Country, 2023-2031

    Figure 29: North America Spine Biologics Market Value Share Analysis, by Product, 2022 and 2031

    Figure 30: North America Spine Biologics Market Attractiveness Analysis, Product, 2023-2031

    Figure 31: North America Spine Biologics Market Value Share Analysis, by Surgery Type, 2022 and 2031

    Figure 32: North America Spine Biologics Market Attractiveness Analysis, Surgery Type, 2023-2031

    Figure 33: North America Spine Biologics Market Value Share Analysis, by Application, 2022 and 2031

    Figure 34: North America Spine Biologics Market Attractiveness Analysis, by Application, 2023-2031

    Figure 35: North America Spine Biologics Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 36: North America Spine Biologics Market Attractiveness Analysis, by End-user, 2023-2031

    Figure 37: Europe Spine Biologics Market Value (US$ Mn) Forecast, 2017-2031

    Figure 38: Europe Spine Biologics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 39: Europe Spine Biologics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 40: Europe Spine Biologics Market Value Share Analysis, by Product, 2022 and 2031

    Figure 41: Europe Spine Biologics Market Attractiveness Analysis, Product, 2023-2031

    Figure 42: Europe Spine Biologics Market Value Share Analysis, by Surgery Type, 2022 and 2031

    Figure 43: Europe Spine Biologics Market Attractiveness Analysis, by Surgery Type, 2023-2031

    Figure 44: Europe Spine Biologics Market Value Share Analysis, by Application, 2022 and 2031

    Figure 45: Europe Spine Biologics Market Attractiveness Analysis, by Application, 2023-2031

    Figure 46: Europe Spine Biologics Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 47: Europe Spine Biologics Market Attractiveness Analysis, by End-user, 2023-2031

    Figure 48: Asia Pacific Spine Biologics Market Value (US$ Mn) Forecast, 2017-2031

    Figure 49: Asia Pacific Spine Biologics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 50: Asia Pacific Spine Biologics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 51: Asia Pacific Spine Biologics Market Value Share Analysis, by Product, 2022 and 2031

    Figure 52: Asia Pacific Spine Biologics Market Attractiveness Analysis, Product, 2023-2031

    Figure 53: Asia Pacific Spine Biologics Market Value Share Analysis, by Surgery Type, 2022 and 2031

    Figure 54: Asia Pacific Spine Biologics Market Attractiveness Analysis, by Surgery Type, 2023-2031

    Figure 55: Asia Pacific Spine Biologics Market Value Share Analysis, by Application, 2022 and 2031

    Figure 56: Asia Pacific Spine Biologics Market Attractiveness Analysis, by Application, 2023-2031

    Figure 57: Asia Pacific Spine Biologics Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 58: Asia Pacific Spine Biologics Market Attractiveness Analysis, by End-user, 2023-2031

    Figure 59: Latin America Spine Biologics Market Value (US$ Mn) Forecast, 2017-2031

    Figure 60: Latin America Spine Biologics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 61: Latin America Spine Biologics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 62: Latin America Spine Biologics Market Value Share Analysis, by Product, 2022 and 2031

    Figure 63: Latin America Spine Biologics Market Attractiveness Analysis, Product, 2023-2031

    Figure 64: Latin America Spine Biologics Market Value Share Analysis, by Surgery Type, 2022 and 2031

    Figure 65: Latin America Spine Biologics Market Attractiveness Analysis, Surgery Type, 2023-2031

    Figure 66: Latin America Spine Biologics Market Value Share Analysis, by Application, 2022 and 2031

    Figure 67: Latin America Spine Biologics Market Attractiveness Analysis, by Application, 2023-2031

    Figure 68: Latin America Spine Biologics Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 69: Latin America Spine Biologics Market Attractiveness Analysis, by End-user, 2023-2031

    Figure 70: Middle East & Africa Spine Biologics Market Value (US$ Mn) Forecast, 2017-2031

    Figure 71: Middle East & Africa Spine Biologics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 72: Middle East & Africa Spine Biologics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 73: Middle East & Africa Spine Biologics Market Value Share Analysis, by Product 2022 and 2031

    Figure 74: Middle East & Africa Spine Biologics Market Attractiveness Analysis, Product, 2023-2031

    Figure 75: Middle East & Africa Spine Biologics Market Value Share Analysis, by Surgery Type, 2022 and 2031

    Figure 76: Middle East & Africa Spine Biologics Market Attractiveness Analysis, Surgery Type, 2023-2031

    Figure 77: Middle East & Africa Spine Biologics Market Value Share Analysis, by Application, 2022 and 2031

    Figure 78: Middle East & Africa Spine Biologics Market Attractiveness Analysis, by Application, 2023-2031

    Figure 79: Middle East & Africa Spine Biologics Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 80: Middle East & Africa Spine Biologics Market Attractiveness Analysis, by End-user, 2023-2031

    Figure 81: Global Spine Biologics Market Share Analysis, by Company 2022

Copyright © Transparency Market Research, Inc. All Rights reserved